Improving the outcome of septic shock in children

Current Opinion in Infectious Diseases

Volumn 13, Issue 3, 2000, Pages 253-258

  Kirsch, Erica A ^a   Giroir, Brett P ^b,c  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CLINDAMYCIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY RESPONSE; HOST SUSCEPTIBILITY; HUMAN; NEWBORN SEPSIS; REVIEW; SEPTIC SHOCK;

EID: 0034077992     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200006000-00009     Document Type: Review

References (65)

1. 1 Jafari HS, McCracken GH. Sepsis and septic shock: a review for clinicians. Pediatr Infect Dis J 1992; 11:739-748.
2. 2 Carcillo JA, Cunnion RE. Septic shock. Crit Care Clin 1997; 13:553-574.
3. 3 Anderson MR, Blumer JL. Advances in the therapy for sepsis in children. Pediatr Clin North Am 1997; 44:179-205.
4. 4 Carr R, Modi N, Dore CJ, El-Rifai R, Lindo D. A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation. Pediatrics 1999; 103:796-802. Prophylactic GM-CSF abolishes postnatal neutropenia and sepsis-induced neutropenia.
5. 5 Kocherlakota P, LaGamma EF. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia. Pediatrics 1998; 102:1107-1111. RhG-CSF increases the AND and reduces the incidence of neonatal sepsis in neutropenic neonates.
6. 6 Schibler KR, Osborne KE, Leung LY, Le TV, Baker SI, Thompson DD. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102:6-13. G-CSF did not increase ANC or affect outcome in neutropenic neonates with sepsis.
7. 7 Cartwright KA. Early management on meningococcal disease. Infect Dis Clin North Am 1999; 13:681-684.
8. 8 Pollard AJ, Britto J, Nadel S, DeMunter C, Habibi P, Levin M. Emergency management of meningococcal disease. Arch Dis Child 1999; 80:290-296. A brief review of meningococcal disease with a detailed early management algorithm based on the experience with over 400 children at a large center in the UK.
9. 9 Ceneviva G, Paschall JA, Maffei F, Carcillo JA. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102;e 19. Though retrospective, the most comprehensive study of hemodynamics in pediatric septic shock.
10. 10 Meyer DM, Jessen ME. Results of extracorporeal membrane oxygenation in neonates with sepsis. The Extracorporeal Life Support Organization experience. J Thorac Cardiovasc Surg 1995; 109:419-426.
11. 11 Meyer DM, Jessen ME. Results of extracorporeal membrane oxygenation in children with sepsis. The Extracorporeal Life Support Organization. Ann Thorac Surg 1998; 63:756-761.
12. 12 Goldman AP, Kerr SJ, Butt W, Marsh MJ, Murdoch IA, Paul T, et al. Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet 1997; 349:466-469.
13. 13 Faist E, Kim C. Therapeutic immunomodulatory approaches for the control of systemic inflammatory response syndrome and the prevention of sepsis. New Horiz 1998; 6(Suppl 2):S97-S102.
14. 14 Peters M, Petros A, Dixon G, Inwald D, Nigel K. Acquired immunoparalysis in paediatric intensive care: prospective observational study. BMJ 1999; 319:609-610. Following the initial pro-inflammatory state, a stage of immunoparalysis ensues, during which the child is at high risk of superinfection.
15. 15 deBont ES, Martens A, vanRaan J, Samson G, Fetter WP, Okken A, et al. Diagnostic value of plasma levels of tumor necrosis factor alpha (TNF alpha) and interleukin-8 (IL-B) in newborns with sepsis. Acts Pasdiatr 1994; 83:696-699.
16. 16 Ng PC, Cheng SH, Chui KM, Fok TF, Wong MY, Wong W, et al. Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch Dis Child 1997; 77:221F-227F.
17. 17 Doughty LA, Kaplan SS, Carcillo JA. Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med 1996; 24:1137-1143.
18. 18 Van Deuren M, van der Ven-Jongekrijg J, Bartelink AK, van Dalen R, Sauerwein RW, vanderMeer JW. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995; 172:433-439.
19. 19 Van Deuren M, van der Ven-Jongekrijg J, Demacker PN, Bartelink AK, van Dalen R, Sauerwein RW, et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994; 169:157-161.
20. 20 Panero A, Pacifico L, Rossi N, Mancuso G, Stegagno M, Chiesa C. Interleukin 6 in neonates with early and late onset infection. Pediatr Inf Dis J 1997; 16:370-375.
21. 21 Doellner H, Amtzen KJ, Haereid PE, Aag S, Austgulen R. lnterleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr 1996; 132:295-299.
22. 22 Doellner H, Arntzen KJ, Haersid PE, Aag S, Brubakk AM, Austgulen R. Increased serum concentrations of soluble tumor necrosis factor receptors p55 and p75 in early onset neonatal sepsis. Early Human Devel 1998; 52:251-261.
23. 23 Onal EE, Kitapci F, Dilmen U, Adam B, lnterleukin-6 concentrations in neonatal sepsis. Lancet 1999; 353:239-240.
24. 24 Silveira RC, Procianoy RS. Evaluation of interleukin-6, tumor necrosis factor-alpha and interleukin-1 beta for early diagnosis of neonatal sepsis. Acta Paediatr 1999; 88:585-586.
25. 25 deBont ES, deLeij LH, Okken A, Baarsma R, Kimen JL. Increased plasma concentrations of interleukin-1 receptor antagonist in neonatal sepsis. Pediatr Res 1995; 37:626-629.
26. 26 Samson LM, Allen UD, Creery DW, Diaz-Mitoma F, Singh RM. Elevated interleukin-1 receptor antagonist levels in pédiatric sepsis syndrome. J Pediatr 1997; 131:587-591.
27. 27 Kuster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, at al. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet 1996; 352; 1271-1277. IL-1Ra and IL-6 can predict neonatal sepsis 2 days before clinical diagnosis.
28. 28 Derkx B, Marchant A, Goldman M, Bijlmer R, vanDeventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171:229-232.
29. 29 Doughty L, Carcillo JA, Kaplan S, Janosky J. The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure. Chest 1998; 113:1625-1631.
30. 30 Hazelzet JA, deGroot R, vanMierlo G, Joosten KFM, vanderVoort E, Eerenberg A, et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998; 66:5350-5356.
31. 31 Shi Y, Li HQ, Shen CK, Wang JH, Qin SW, Liu R, Pan J. Plasma nitric oxide levels in newborn infants with sepsis. J Pediatr 1993; 123:435-438.
32. 32 Wong HR, Carcillo JA, Burckart G, Kaplan SS. Nitric oxide production in critically ill patients. Arch Dis Child 1996; 74:482-489.
33. 33 Wong HR, Carcillo JA, Burckart G, Shah N, Janosky JE. Increased serum nitrite and nitrate concentrations in children with the sepsis syndrome. Crit Care Med 1996: 23:835-642.
34. 34 Doughty L, Carcillo JA, Kaplan S, Janosky J. Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis. Crit Care Med 1998; 26:157-182.
35. 35 Spack L, Havens PL, Griffith OW. Measurements of total plasma nitrite and nitrate in pediatric patients with the systemic inflammatory response syndrome. Crit Care Med 1997; 26:1071-1078.
36. 36 Duke T, South M, Stewart A. Activation of the L-arginine nitric oxide pathway in severe sepsis. Arch Dis Child 1997; 76:203-209.
37. 37 Smulian JC, Vintzileos AM, Lai YL, Santiago J, Shen-Schwarz S, Campbell WA. Maternal chorioamnionitis and umbilical vein interleukin-6 levels for identifying early neonatal sepsis. J Maternal-Fetal Med 1999; 8:88-94.
38. 38 Kultursay N, Kantar M, Akisu M, Huseyinov A, Coker I. Platelet-activation factor concentrations in healthy and septic neonates. Eur J Pediatr 1999; 158:740-741.
39. 39 Riordan FA, Bestwick K, Thomson AP, Sills JA, Hart CA. Plasma fibronectin levels in meningococcal disease. Eur J Pediatr 1999; 158:81-82.
40. 40 Baines PB, Stanford S, Bishop-Bailey D, Sills J, Thomson AP, Mitchell JA, et al. Nitric oxide production in meningococcal disease is directly related to disease severity. Crit Care Med 1999; 27:1187-1190.
41. 41 Baines PB, Marzouk O, Thomson APJ, Sills JA, Riordan FAI, Hart CA. Endothelial cell adhesion molecules in meningococcal disease. Arch Dis Child 1999; 80:74-76.
42. 42 Krafte-Jacobs B, Brilli R. Increased circulating thrombomodulin in children with septic shock. Crit Care Med 1998; 26:933-938.
43. 43 Powars DR, Rogers ZR, Patch MJ, McGee WG, Francis RB. Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S. N Engl J Med 1987; 317:571-572.
44. 44 Brandtzaeg P, Sandset PM, Joo GB, Ovstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55:459-470.
45. 46 Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49:5-7.
46. 46 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79:124-130.
47. 47 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:1165-1172.
48. 48 Kornelisse RF, Hazelzet JA, Savelkoul HFJ, Hop WC, Suur MH, Borsboom AN, et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173:1148-1156.
49. 49 Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, at al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251. HMG-1 identified as a late mediator of endotoxin lethality in mice.
50. 50 Derkx B, Wittes J, McCloskey R, and the European Pediatric Meningococcal Septic Shock Trial Study Group. Randomized placebo controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin Infect Dis 1999; 28:770-777. HA-1A is of no benefit in children with meningococcemia, though a trend towards enhanced survival.
51. 51 Kishi K, Hirai K, Hiramatsu K, Yamasaki T, Nasu M. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli 055:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1β. Antimiorob Agents Chemother 1999; 43:616-622. Clindamycin suppresses endotoxin release from ceftazidime-treated E. coli.
52. 52 Levy O, Martin S, Eichenwald E, Ganz T, Valore E, Carroll SF, et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 1999; 104:1327-1333. Neutrophils of newborns are deficient in BPI, a central effector of antibacterial activity against Gram-negative bacteria.
53. 53 Giroir BP, Quint PA, Barton P, Kirsch EA, Kitchen L, Goldstein B, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997; 350:1439-1443.
54. 54 Maysouye P, Gunning K, Pittet JF, Suter PM, Morel DR. Xanthine derivative HWA 138 attenuates hemodynamic and oxygen uptake dysfunction secondary to severe endotoxin shock in sheep. Circ Shock 1992; 36:113-119.
55. 55 Lundblad R, Ekstrom P, Giercksky KE. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995; 3:210-215.
56. 56 Lauterbach R, Pawlik D, Kowalcsyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999; 27:807-814. Penoxifylline decreases TNF and IL-6 levels and reduces mortality in premature infants with sepsis.
57. 57 Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 1997; 157:389-393.
58. 58 Platnov AE, Shipulin GA, Verahinina IV, Dankert J, vandeWinkel JGJ, Kuijper EJ. Association of human FcγRlla (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998; 27:746-750. Certain allotypes of FcγRlla are associated with increased susceptibility to severe meningococcal disease.
59. 59 Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999; 353:1049-1053. Allelic variation in MBL is a determinant of meningococcal disease susceptibility.
60. 60 Garred P, Madsen HO, Svejgaard A, Michaelsen TE. Mannose-binding lectin and meningococcal disease. Lancet 1999; 354:336.
61. 61 Bax WA, Cluysenaer OJJ, Bartelink AKM, Aerts PC, Ezekowitz RAB, vanDijk H. Association of familial deficiency of mannose-binding lectin and meningococcal disease. Lancet 1999; 354:1094-1095.
62. 62 Westendorp RGJ, Langarmans JAM, Huizinga TWJ, Elouali AH, Verweij CL, Boomsma DI, Vandenbrouke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349:1912-1915. Heritablility of production of TNF and IL-10 in response to endotoxin is associated with increased risk for fatal meningococcal disease.
63. 63 Hermans PWM, Hibberd ML, Booy R, Daramola O, Hazelzet JA, deGroot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 1999; 354:556-560. Genetic predisposition to produce high concentrations of PAI-1 is associated with poor outcome of meningococcal sepsis.
64. 64 Westendorp RGJ, Hottenga J, Slagboom PE, Variation I plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-563. Variation in the PAI-1 gene influences the development of septic shock in patients with meningococcal disease.
65. L is associated with increased complications in patients with purpura fulminans.